The expression of genes that we showed are involved in the prognosis of PFS of prostate cancer patients, PTPN2 and FMOD, did not change the global expression between prostate cancer and non-transformed tissue according to the criteria used (|log2FC| ≥ 1 and FDR p-value < 0.01). This evidence concerns the gene FMOD and prostate cancer.